1,721 followers
RT @FrontImmunol: New Research: Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas: The prognosis of malignant gl…
RT @FrontImmunol: New Research: Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas: The prognosis of malignant gl…
New Research: Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas: The prognosis of malignant gliomas remains poor, with median survival fewer than 20 months and a 5-year survival rate merely 5%. Their primary… https://t.co/QWqtu77